The Anti-Freaze-F trial is looking at the feasibility of conducting a large randomised controlled trial to assess whether an intra-articular injection of anti-TNF (Adalimumab) can reduce pain and improve function in people with pain predominant early-stage frozen shoulder.
We aim to recruit 84 men and women from across England with early stage Frozen shoulder (usually within the first 3 months of experiencing symptoms).
Frozen shoulder (adhesive capsulitis) is extremely painful and debilitating, affecting a person’s ability to perform daily tasks and sleep. It occurs when the capsule surrounding the shoulder joint becomes inflamed, thickened and tight.
It presents in three over-lapping phases: i) early painful inflammatory stage (lasts 3-9 months); ii) increased stiffness and impaired function (4-12 months); iii) final thawing phase (12-48 months).
Third site open to recruitment is Sandwell and West Birmingham NHS Trust
First participant recruited at University Hospitals Birmingham
First site to open to recruitment is United Lincolnshire Hospitals
Seocnd site to open to recruitment is University Hospitals Birmingham
The Anti-Freaze-F Trial received REC, MHRA and HRA Approvals in December 2021.